Imeik Technology Development Co

Imeik Technology Development Co Capital Intensity

The Capital Intensity Ratio of Imeik Technology Development Co (300896.SZ) as of Nov 13, 2026 is 367.52 %. In the previous year, Capital Intensity Ratio was 275.66 % — a change of 33.32% (higher).

Capital Intensity

367.52 %

YoY

33.32%

Last updated:

Capital Intensity Ratio of Imeik Technology Development Co is 2025 367.52 % . Capital Intensity Ratio of Imeik Technology Development Co was 2024 275.66 % . It decreases by 33.32% higher compared to the previous year.

The Imeik Technology Development Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
144.42 CNY
Jan 1, 2019
133.34 CNY
Jan 1, 2020
658.64 CNY
Jan 1, 2021
364.12 CNY
Jan 1, 2022
322.80 CNY
Jan 1, 2023
238.81 CNY
Jan 1, 2024
275.66 CNY
Jan 1, 2025
367.52 CNY
The Imeik Technology Development Co Capital Intensity history
YEARCapital IntensityYoY
367.52 %+33.32%
275.66 %+15.43%
238.81 %-26.02%
322.80 %-11.35%
364.12 %-44.72%
658.64 %+393.96%
133.34 %-7.67%
144.42 %-18.94%
178.17 %-20.11%
223.02 %+44.44%
154.40 %+10.16%
140.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Capital Intensity Ratio of Imeik Technology Development Co is 367.52 % in 2025.

Capital Intensity Ratio of Imeik Technology Development Co changed from 275.66 % to 367.52 %, representing a 33.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co